secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0001100682-25-000003
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Labs provides preliminary 2025 outlook: revenue decline, CDMO client losses, potential impairment
--------------------------------------------------------------------------------

- Expects 2025 revenue to decline organically in similar range as estimated 2024; DSA demand consistent with H2 2024.
- CDMO revenue headwind: a cell therapy client terminated commercial agreement; lower revenue from another cell therapy client; ~1% consolidated revenue growth drag.
- Site consolidation actions (~0.5%) and FX (>1%) also expected to reduce reported revenue in 2025.
- Non-GAAP operating margin expected modestly below estimated 2024 level; cost savings cannot fully offset lower revenue.
- Assessing recoverability of goodwill and long-lived assets for potential impairment due to CDMO business challenges.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000110068225000003/0001100682-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000110068225000003/crl-20250114.htm
  HTML page:      https://secwatch.observer/filing/0001100682-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer